Wonder drug Dasatinib gives hopes to leukemia patients
The company Bristol-Myers Squibb Co at Boston told the press that the ... This drug is very effective in the decreasing the leukemia cells fr...Chronic myeloid leukemia (CML) is usually presented in three diffe...Out of the 107 patients in the accelerated stage 31% who did not rea...Out of the 74% in the blast stage (aggressive form) 29% of the patie...
The company Bristol-Myers Squibb Co at Boston told the press that the drug Dasatinib has led to reduction in the number of patients with Chronic myeloid leukemia (CML).//
This drug is very effective in the decreasing the leukemia cells from the bone marrow than the previously used drug Gleevec.
Chronic myeloid leukemia (CML) is usually presented in three different stages –
Chronic stage, accelerated stage and the blast stage.
Dasatinib was tried on all these stages of leukemia patients and the results were
Out of the186 patients who are in the chronic stage, 45% of the patients attained complete elimination of the leukemia cells from the marrow.
Out of the 107 patients in the accelerated stage 31% who did not react to Gleevec responded positively to Dasatinib.
Out of the 74% in the blast stage (aggressive form) 29% of the patients attained complete elimination of the leukemia cells.
This is a boon to all those patients who do not react to Gleevec which is the treatment for Leukemia.
This drug will soon reach the markets by the end of the current year or the beginning of the next year.
Gleevec was a Swiss product and in 2001after approved by the Food and Drug Administration, made to the markets as the drug which attacks the BCR-ABL protein which results in the abnormal rise of leukocytes.
But with this drug some patients (20% of CML) did not respond to the drug or initially responded but later became resistant to the drug.
The mechanism of the drug action is that it attacks and prevents several proteins (BCR-ABL & SRC) in the same time. SRC is believed to help the leukemia cells to take the alternate pathway and become resistant to Gleevec, but Dasatinib prevents the action of SRC.
The toxicity level of Dasatinib is not more than Gleevec and it has to be brought in to the market for commercial use as the statistics show that in the current year the number of ch '"/>
(Date:12/1/2009)... Craig Moskowitz, a fourth-year medical student at...o go into internal medicine to help fulfill an unm...k, NJ (PRWEB) December 1, 2009 -- Having distingui...censing examinations, Craig Moskowitz--a fourth-ye...dicine--knew he could go into any area of medicine...
(Date:12/1/2009)... A new mind-body medicine study conducted by The A...y meditation, diaphragmatic breathing and yoga cre...sical, mental and emotional health benefits. , ...ember 1, 2009 –– A new retrospective, ...and yoga practices learned by students who attende...
(Date:12/1/2009)... All Federal and Georgia State Retirees who are Me...s new benefit is part of the Medicare Advantage Pr...or service (PFFS) Options offered by CIGNA, Blue C...manente. Atlanta Hearing Associates has three offi...ee / Greensboro, GA and Lake Sinclair / Milledgevi...
(Date:12/1/2009)...c. 1 What many spa clients have th...ournalists has proclaimed in the 2009 AsiaSpa Awar...Taking five citations including "Asian Spa Capital... in the fifth AsiaSpa Awards, presented by AsiaSpa...llness publication, during a glittering ceremony r...
(Date:12/1/2009)...tion from annual mammography screening may increas...lial predisposition to breast cancer, according to...the Radiological Society of North America (RSNA). ...reening is very important, but a careful approach ...creening young women, particularly under age 30," ...
...y of ophthalmologists across the nation, virtually...cations can enhance the ocular comfort of glaucoma...e glaucoma medications can enhance patient quality...ervative-free beta-blocker is available. , , The ...
...ion (NYSE: HAE ) announced today that Richard Me...tive April 2, 2009. Mr. Meelia is Chairman, Presi... products company. He is retiring from Haemonetic...appreciate Rich,s leadership and guidance during h...
...ability, researcher says , , MONDAY, April...broccoli sprouts appeared to reduce the risk of st...nese trial. , Gastric cancer thus joins a long lis...der, skin and lung, among others. , "I have to be ...
...unts; Membership in ECP Global Communication Inter...Communications, Inc. ( www.feintuchcommunications...ustry veteran and former journalist Henry Feintuch... ) , , Mr. Feintuch, formerly managing partner, ...
...or Medical Benefits, Movement to Direct Contractin...o Data from HealthLeaders-InterStudy , , NASHVILL...eading provider of managed care market intelligenc...manager (PBM), also known as a "carve-out," increa...
...of Grants Office, LLC and a national leader in pro...ailable for on-camera and telephone interviews. , ... worked to develop an extensive pool of knowledge ...ding (in addition to ongoing annual grant funding)...
(Date:11/30/2009)...re-FirstCall/ -- Henry Schein, Inc., (Nasdaq: HSI...and services, announced today that Steven Paladino... Financial Officer, will present at the NASDAQ OMX...9. The conference is taking place at the Mayfair ...n is scheduled to begin at 9:15 a.m. EST and can b...
(Date:11/30/2009)...swire-FirstCall/ -- MedQuist Inc. (Nasdaq: MEDQ...cal documentation services, is featuring a new sol...th America (RSNA) conference in Chicago. Called S...SpeechQ(TM), the company,s real-time interactive s... radiologists. MedQuist has integrated SpeechQ wi...
(Date:11/30/2009)...e/ -- Reportlinker.com announces that a new market..., Inflammatory Disorders: Therapies That Suppre...ww.reportlinker.com/p0165600/Inflammatory-Disorder...sponse.html ,, The human immune system can go ...cing an exaggerated response to a foreign substanc...
...to preventing bone loss focus on early screening a...osteoporosis are staggering. 75 million baby boome...ghtening its grip on their bones. Osteoporosis ... ) also contributes to an estimated 1.5 million bo...ding to new information presented today at the 200...
...maceutical research and biotechnology companies ar...o treat two of the country,s top killers. Accordin...rch and Manufacturers of America (PhRMA) on medici...es are in development to treat heart disease and s...g commitment of our scientists and companies to im...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...